Impedimed Limited Stock Fundamentals
| IPDQF Stock | USD 0.05 0.00 0.00% |
ImpediMed Limited fundamentals help investors to digest information that contributes to ImpediMed's financial success or failures. It also enables traders to predict the movement of ImpediMed Pink Sheet. The fundamental analysis module provides a way to measure ImpediMed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImpediMed pink sheet.
ImpediMed |
ImpediMed Limited Company Profit Margin Analysis
ImpediMed's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current ImpediMed Profit Margin | (1.88) % |
Most of ImpediMed's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImpediMed Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, ImpediMed Limited has a Profit Margin of -1.8809%. This is 83.22% lower than that of the Healthcare sector and 65.55% lower than that of the Medical Devices industry. The profit margin for all United States stocks is 48.1% higher than that of the company.
ImpediMed Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImpediMed's current stock value. Our valuation model uses many indicators to compare ImpediMed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImpediMed competition to find correlations between indicators driving ImpediMed's intrinsic value. More Info.ImpediMed Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImpediMed's earnings, one of the primary drivers of an investment's value.ImpediMed Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImpediMed's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImpediMed could also be used in its relative valuation, which is a method of valuing ImpediMed by comparing valuation metrics of similar companies.ImpediMed is currently under evaluation in profit margin category among its peers.
ImpediMed Fundamentals
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.88) % | |||
| Operating Margin | (2.00) % | |||
| Current Valuation | 81.27 M | |||
| Shares Outstanding | 1.79 B | |||
| Shares Owned By Insiders | 13.73 % | |||
| Shares Owned By Institutions | 14.96 % | |||
| Price To Earning | (8.46) X | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 9.22 X | |||
| Revenue | 10.49 M | |||
| Gross Profit | 9.16 M | |||
| EBITDA | (18.77 M) | |||
| Net Income | (19.87 M) | |||
| Cash And Equivalents | 40.73 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 170 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.44 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (15.66 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 73 | |||
| Beta | 2.67 | |||
| Market Capitalization | 78.57 M | |||
| Total Asset | 58.7 M | |||
| Retained Earnings | (150 M) | |||
| Working Capital | 83 M | |||
| Current Asset | 88 M | |||
| Current Liabilities | 5 M | |||
| Net Asset | 58.7 M |
About ImpediMed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImpediMed Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImpediMed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImpediMed Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia. Impedined operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 73 people.
Currently Active Assets on Macroaxis
Other Information on Investing in ImpediMed Pink Sheet
ImpediMed financial ratios help investors to determine whether ImpediMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImpediMed with respect to the benefits of owning ImpediMed security.